Literature DB >> 16804163

On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin.

M Zouhair Atassi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16804163     DOI： 10.1099/mic.0.28862-0

Source DB:  PubMed          Journal:  Microbiology        ISSN： 1350-0872            Impact factor:   2.777


× No keyword cloud information.
  5 in total

Review 1.  Clinical relevance of botulinum toxin immunogenicity.

Authors:  Reiner Benecke
Journal:  BioDrugs       Date:  2012-04-01       Impact factor: 5.807

2.  Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?

Authors:  Jürgen Frevert; Dirk Dressler
Journal:  Biologics       Date:  2010-12-09

3.  Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data.

Authors:  Andy Pickett
Journal:  Clin Ophthalmol       Date:  2011-09-09

4.  Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm.

Authors:  Juwan Park; Michael S Lee; Andrew R Harrison
Journal:  Clin Ophthalmol       Date:  2011-06-01

Review 5.  Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.

Authors:  Francesco Scaglione
Journal:  Toxins (Basel)       Date:  2016-03-04       Impact factor: 4.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.